Ovarian Cancer Diagnostics Market

Ovarian Cancer Diagnostics is the disease characterized by the abnormal growth of cells in the ovarian tissue. Ovarian Cancer Diagnostics Market is the most common type of cancer in the women. Types of ovarian cancer include a stromal tumour, germ cell tumour, and epithelial tumours. Symptoms associated with ovarian cancer include abdominal pressure, swelling, loss of appetite, urinary urgency, low back pain, and pelvic discomfort among others. Ovarian cancer can be diagnosed by MRI, CT, PET scans, blood tests, ultrasound, and pelvic examination.


Increase in the ageing women population, rise in technological advancements for disease diagnosis, increase in the prevalence of ovarian cancer around the globe, and rise in healthcare awareness among key stakeholders are anticipated to bolster the ovarian cancer diagnostics market. Furthermore, highly developed healthcare infrastructure in developed countries, a rise in income per capita, and government initiative programs for increasing awareness about the ovarian cancer are expected to boost the ovarian cancer market growth over the forecast period. However, a high cost of the diagnostic procedure, lack of accuracy in disease diagnosis, stringent regulatory policies for diagnostic device approvals, and lack of early diagnostic tests and early warning systems might hamper the ovarian cancer diagnostics market over the forecast timeframe.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-ovarian-cancer-diagnostics-market/#ulp-4H8Z4LpNMLEuOnnx

Ovarian cancer diagnostics market is segmented on the basis of diagnosis type, disease type, and end user

Based on the diagnosis type, ovarian cancer diagnostics market is segmented into the following:
• Biopsy
• MRI scan
• CT scan
• PET scan
• Ultrasound
• Blood test
• Others

Based on the disease type, ovarian cancer diagnostics market is segmented into the following:
• Stromal tumour
• Germ cell tumour
• Epithelial tumour
• Primary peritoneal carcinoma

Based on the end user, ovarian cancer diagnostics market is segmented into the following:
• Hospitals
• Clinics
• Diagnostic centres
• Others

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-ovarian-cancer-diagnostics-market/#ulp-c654SbFYO64MsOhu



Ovarian cancer diagnostics market is growing at a significant CAGR owing to increase in the prevalence of ovarian cancer around the globe. According to World Cancer Research Fund International, about 239,000 new cases were diagnosed in 2012. Acquisitions and mergers, collaborations, innovation of novel diagnostic procedures are key strategies followed by the companies for increasing their revenue. For instance, In January 2015, VolitionRx Ltd. collaborated with Singapore General Hospital for development of blood-based test for ovarian cancer diagnosis. Moreover, fund raising by the market players for the innovation of novel diagnostic procedures also propels the market growth.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-ovarian-cancer-diagnostics-market/#ulp-14mlyhjMGhVjZqa3


Geographically, ovarian cancer diagnostics market is segmented into North America, Asia Pacific, Europe, Middle East and Africa, and Latin America. Due to increase in the prevalence of ovarian cancer in U.S. (according to Centres for Disease Control and Prevention 2014, about 21,161 women diagnosed and 14,195 women died of ovarian carcinoma), rise in the healthcare expenditure are propelling the ovarian cancer diagnostics market growth in North America region. Europe exhibiting significant growth in ovarian cancer diagnostics market which is attributed to upsurge in aging women population, highly developed healthcare infrastructure, and increase in the disease prevalence majorly in Estonia, Latvia, Lithuania, and Croatia are expected to fuel the ovarian cancer diagnostics market. ‘Asia Pacific holds significant share owing to rise in aging women population majorly in Japan, China, and India, increase in the healthcare expenditure, and adoption of novel techniques for diagnosis.


Some of the players in ovarian cancer diagnostics market are AstraZeneca Plc. (U.K.), Illumina, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Siemens AG (Germany), Roche Holding AG (Switzerland), Myriad Genetics, Inc. (U.S.), Epigenomics AG (Germany), Thermo Fischer Scientific Inc. (U.S.), VolitionRx Ltd. (Singapore), and Abcodia Ltd. (U.K.) to name a few.



Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-ovarian-cancer-diagnostics-market/
About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised which follow a holistic approach to solve needs of market research services based on our client needs.

Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI’s approachable strategies are to help clients to make key decisions for business growth.

Precision Business Insights vision is to become most valued partner to fortune 500 companies by providing agile, accurate, and actionable market insights

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com